Quebec City, October 25, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) announced today that it will report Financial Results for the third quarter of 2011, for the period ending September 30 2011, on Wednesday, November 2, 2011. TSO3 will host a Conference Call and a Webcast at 10:30 A.M. (ET) the same day to discuss financial results and to update on recent activities.
Analysts and Institutional Investors are invited to participate to the call. The numbers to dial for access are 1-514-940-2795 (Montréal area), 1-416-644-3425 (Toronto area) or the Toll-Free number 1-877-974-0445. Other interested parties may listen to the live Webcast of the Conference Call accessible via CNW’s Website at: http://www.newswire.ca/en/webcast/detail/864239/916885. The Webcast will be archived for 90 days.
TSO3 enables better health care through the development of innovative, low-temperature medical device sterilization systems and offers these solutions through licensing agreements to reputable channel partners for global commercial reach.
The TSO3 sterile reprocessing solutions answer the global and growing need for economical and fast turnaround of a wide range of medical instruments. These solutions address cutting-edge, high-demand devices – such as flexible endoscopes – and support the development of increasingly sophisticated medical devices and techniques.
At TSO3 ‘s core, is its ability to conduct rapid research, development and prototyping as well as validating biocompatibility and functionality of innovative medical reprocessing systems. TSO3 maintains a rigorous quality system as well as in-house expertise for regulatory submissions.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts